Account wins from the 04/28/06 News Brief

Share this article:
The Navicor Group, an inVentiv Health company and a full-service advertising agency that focuses exclusively on the areas of oncology and immunology, has been named agency of record for Hepsera (adefovir dipivoxil), an orally administered prescription medicine for the treatment of chronic hepatitis B. Hepsera was developed by Gilead Sciences. The drug was approved by the FDA in September 2002. The Navicor Group’s assignment includes the development of strategic and creative marketing communications for the product.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.